XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2026

Conditions

Rectal CancerMSS

Interventions

DRUG

Cadonilimab

10mg/kg iv on day 1, every 21 day

DRUG

Oxaliplatin

130mg/m2 iv on day 1, every 21 day

DRUG

Capecitabine

1000mg/m2 po bid on day 1 to 14, every 21 day

Trial Locations (1)

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER